Ticker: LLY

Eli Lilly

Pharma Healthcare Drug Manufacturers - General

Price 1123.04

Reco Hold Potential 60 Risk 70 Updated 2026-09-11

Official website

Forecast impact

played out

Target -16.3% target fill 119.5%

Reaction D5 pending · D10 pending fresh confirmed · market trust

Impact Potential 0 · Risk 0 valid until 2026-10-10

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Eli Lilly is a global healthcare company that focuses on the discovery, development, and commercialization of pharmaceuticals. Its core products include treatments for diabetes, oncology, immunology, and neurodegenerative diseases. Major business segments consist of diabetes care, oncology, and neuroscience, with significant revenue generated from insulin products and cancer therapies. The company is recognized for its innovative drug pipeline and strong market presence in the healthcare sector.

Investment Profile

Eli Lilly's stock is positioned as a balanced investment, appealing to investors seeking moderate growth and some income through dividends. The company demonstrates stable revenue growth and a consistent dividend yield, making it suitable for those looking for a mix of capital appreciation and income. Its established market presence and ongoing product development contribute to a favorable risk-return profile.

Category: Pharma Sector: Healthcare Industry: Drug Manufacturers - General Investment style: Growth Horizon: Long-term Company type: Blue Chip Company type: Market Leader Experience: Basic

Fundamental metrics (experimental) Updated: 2026-09-06

EPS (TTM) — earnings per share for the last 12 months, $: 29.85
Revenue QoQ — quarter-over-quarter revenue growth: 16.0%
EPS surprise: 30.9%
20d volatility: 1.8%
Dividend yield: 0.6%
last ex-date: 2026-08-14

AI recommendation changes

Date	Before	After	Reason
2026-09-06	Buy	Hold	Mixed performance; cautious due to high risk factors.
2026-08-06	Hold	Buy	Strong fundamentals and positive momentum support growth outlook.
2026-07-31	Buy	Hold	Weak momentum and high risk; cautious approach advised.
2026-05-18	Hold	Buy	Strong fundamentals and positive short-term momentum.
2026-05-10	Buy	Hold	Weak momentum and high risk; mixed analyst signals.
2026-05-08	—	Buy	Solid fundamentals but mixed momentum signals.
2026-05-08	Buy	Buy	Компания показывает стабильный рост выручки и положительные сюрпризы по EPS, однако недавние колебания цен и негативная динамика на более длительных сроках вызывают осторожность.
2026-04-29	Hold	Buy	Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по прибыли, однако недавние колебания цен акций и снижение на более длительных горизонтах вызывают опасения. Рекомендуется удерживать акции
2026-04-17	Buy	Hold	Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по EPS, однако недавние колебания цен акций и снижение на коротких временных интервалах могут указывать на повышенные риски.
2026-04-09	Hold	Buy	Компания Eli Lilly демонстрирует стабильный рост выручки и положительные результаты по EPS, что указывает на сильные финансовые показатели. Несмотря на недавние колебания цен, долгосрочные тренды и позитивные прогнозы де
2026-03-22	Buy	Hold	Компания Eli Lilly демонстрирует сильный рост выручки и положительный сюрприз по прибыли, однако недавнее снижение цен акций и высокая волатильность могут указывать на риски в краткосрочной перспективе.
2026-02-06	Hold	Buy	Компания Eli Lilly демонстрирует сильный рост за последние 120 дней, однако недавнее падение на 7.79% может указывать на краткосрочные риски. Рекомендуется удерживать акции до более ясной картины.
2026-01-29	Buy	Hold	Компания Eli Lilly демонстрирует сильный рост за последние 60 и 120 дней, однако недавние колебания цен указывают на возможную волатильность. Рекомендуется удерживать акции до более ясных сигналов о дальнейшем движении.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-09-10	HSBC	Target Raised	850 → 940	1124.16
2026-08-07	UBS	Target Raised	1370 → 1376	1177.33
2026-08-06	Cantor Fitzgerald	Target Raised	1350 → 1410	1181
2026-08-06	Morgan Stanley	Target Raised	1347 → 1419	1169.86
2026-08-06	Wells Fargo	Target Raised	— → 1330	1169.86
2026-08-06	BMO Capital	Target Raised	— → 1400	1169.86
2026-07-14	Bernstein	Target Raised	— → 1385	1185.08
2026-07-13	UBS	Target Raised	1250 → 1425	1189.91003
2026-07-13	Guggenheim	Target Raised	— → 1273	1188.58
2026-07-09	UBS	Target Raised	1281 → 1370	1222.125
2026-07-08	Truist Financial	Target Raised	— → 1370	1227.07
2026-07-08	RBC Capital	Target Raised	1250 → 1500	1229.21997
2026-07-08	Morgan Stanley	Target Raised	1344 → 1347	1235.56
2026-07-06	Cantor Fitzgerald	Target Raised	— → 1350	1210.5
2026-06-25	Leerink Partners	Target Raised	1119 → 1232	1117.26
2026-06-22	Berenberg Bank	Target Raised	1050 → 1135	1111.67
2026-06-09	Jefferies	Target Raised	1330 → 1350	1143.35
2026-05-26	HSBC	Target Raised	— → 1251	1065
2026-05-26	Leerink Partners	Update	— → 1119	1065
2026-05-21	Wolfe Research	Target Raised	1325 → 1350	1037.82007
2026-05-05	Barclays	Target Raised	1350 → 1400	967.93
2026-05-01	Morgan Stanley	Target Raised	1327 → 1344	961.555
2026-05-01	Cantor Fitzgerald	Target Raised	1205 → 1230	970.675
2026-04-10	Morgan Stanley	Target Raised	1313 → 1327	939.31
2026-03-13	Jefferies	Update	— → 1300	1000.78003
2026-03-06	Deutsche Bank	Update	— → 1285	990.31
2026-03-05	Morgan Stanley	Update	— → 1313	972.5

News Page 5 of 5

Eli Lilly’s Business Development Head Jacob Van Naarden Signals Increased M&A Activity as Company Pursues New Opportunities

06/03/2026, 04:33 AM business announcement healthcare Eli Lilly

Eli Lilly is leveraging its significant financial strength, driven by its successful weight loss drugs, to pursue an aggressive acquisition strategy aimed at diversifying its drug pipeline and expanding into new therapeutic areas. This shift marks a notable change in Lilly's approach to dealmaking as it seeks to capitalize on its recent growth.

Analysts JPMorgan recommend top stocks for June, including Viasat (VSAT) and Eli Lilly (LLY)

06/02/2026, 08:31 AM investing recommendation Analysts: analysts, JPMorgan software telecom Viasat Eli Lilly

JPMorgan's updated list of top investment ideas for June highlights strong performance in U.S. stocks, particularly in technology, and includes new recommendations such as Viasat, which has seen significant growth despite recent volatility.

CVS Health to Restore Coverage of Eli Lilly’s Zepbound and Add Foundayo Obesity Pill to Drug Plans

05/28/2026, 04:34 AM business announcement healthcare CVS Health Eli Lilly

CVS Health's decision to restore coverage for Eli Lilly's Zepbound and add its new obesity pill Foundayo is significant as it enhances patient access to weight loss treatments and strengthens Lilly's competitive position against Novo Nordisk in the market.

Stocks to Watch: AutoZone Declines on Sales Challenges, Eli Lilly Acquires Three Companies, Ferrari Launches Electric Vehicle, and Lear Upgraded by TD Cowen

05/26/2026, 05:34 AM business review auto pharma Micron Advanced Micro Devices Exxon Mobil Intuitive Machines AutoZone Ferrari Chevron Qualcomm Eli Lilly

Several companies are experiencing notable stock movements ahead of the market opening, with AutoZone facing declines due to disappointing international sales, while Eli Lilly's acquisition strategy boosts its stock.

Eli Lilly (LLY) Plans Nearly $4 Billion in Vaccine Acquisitions to Expand Infectious Disease Research

05/26/2026, 05:34 AM announcement healthcare Eli Lilly

Eli Lilly's announcement to acquire three companies for nearly $4 billion highlights its strategic shift towards infectious disease research, which could enhance its market position in vaccine development.

Goldman Sachs Recommends Buying Stocks Unrelated to AI Amid Market Focus on Technology

05/25/2026, 05:33 AM investing recommendation Analysts: analysts, Goldman Sachs finance internet Goldman Sachs Fortinet Chewy Eli Lilly

Goldman Sachs identifies investment opportunities outside the booming AI sector, suggesting that investors consider stocks with strong earnings growth and low sensitivity to AI trends. This approach may help diversify portfolios amid the current market focus on technology.